Auven Therapeutics Mergers and Acquisitions Summary

Private Equity Profile

Auven Therapeutics’ most common sector for investment is life science (100%). The Firm’s most common investment types include venture (60%) and divestiture (20%). In total, Auven Therapeutics has invested in 2 US states and 3 different countries.

In the last 3 years, Auven Therapeutics has exited 1 company. The Firm’s most common exit type is trade sale (75%). Auven Therapeutics’ largest (disclosed) exit occurred in 2015 when it sold Sprout Pharmaceuticals for $1.0B.

Join Mergr to view Auven Therapeutics’ full profile and discover more small private equity firms just like it.

M&A Summary

  • M&A Total Activity9
    • M&A Buy Activity5
    • M&A Sell Activity4
  • Total Sectors Invested 1
  • Total Countries Invested 3
  • M&A Buy/Sell Connections 3
  • M&A Advisors 2

Auven Therapeutics

6501 Redhook Plaza, Suite 201,
St. Thomas, 00802
Virgin Islands (U.S.)
(340) 779-6908
www.auventx.com
info@auventx.com

Auven Therapeutics is a private equity firm focused on investing in life science companies. Auven looks to acquire controlling ownership in promising therapeutic products or platforms and develop programs to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven Therapeutics was established in 2007 and is headquartered in St. Thomas, US Virgin Islands.


Investment Criteria

Sectors of Interest: Life Science

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital

Geographic Preferences: East US, Midwest US, South US, West US

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '15 '16 '17 '18 '19 '20 T
Buy (0.0/yr) # 5 - - - - - 5
Sell (0.4/yr) # 2 1 - - - 1 4
vol $1.2B $40M $1.3B
  9

Most Recent M&A

Company Date Value Type
ADC Therapeutics SA 2020-05-11 - IPO
Epalinges, Switzerland · www.adctherapeutics.com
Ocular Technologies Sarl 2016-10-26 40M USD Add-on Acquisition
Lyme Park, South Africa · www.oculartechnologies.com
Sprout Pharmaceuticals, Inc. 2015-08-20 1.0B USD Add-on Acquisition
Raleigh, North Carolina · www.sproutpharma.com
Spirogen Ltd. 2013-10-15 240M USD Add-on Acquisition
London, United Kingdom · www.spirogen.com
ADC Therapeutics SA 2013-10-15 - Growth Capital
Epalinges, Switzerland · www.adctherapeutics.com
ADC Products 2013-10-01 - Divestiture
, Switzerland
Sprout Pharmaceuticals, Inc. 2012-03-01 - Venture
Raleigh, North Carolina · www.sproutpharma.com
Kolltan Pharmaceuticals, Inc. 2010-01-19 - Venture
New Haven, Connecticut · www.kolltan.com
Spirogen Ltd. 2009-01-01 - Venture
London, United Kingdom · www.spirogen.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 1 (100%) - 5 (100%) -
Total 1 - 5 -

Acquisitions By Geo

State/Country Current # Value All-time # Value
Switzerland 1 (100%) - 2 (40%) -
United States - - 2 (40%) -
  North Carolina - - 1 (20%) -
  Connecticut - - 1 (20%) -
United Kingdom - - 1 (20%) -
Total 1 - 5 -

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture - - 3 (60%) -
Divestiture 1 (100%) - 1 (20%) -
Growth Capital - - 1 (20%) -
Total 1 - 5 -

Exits by Deal Type

Type Total # Value
Trade Sale 2 (50%) 1.2B (97%)
Trade Sale - Public Company 1 (25%) 40M (3%)
IPO 1 (25%) -
Total 4 $1.3B

Top M&A Advisors

Financial Deals
MTS Health Partners LP
1
Legal Deals
Akin Gump Strauss Hauer & Feld LLP
1

Deal Values

sell # Total
> $1B 1 $1.0B
$100M to $1B 1 $240M
< $100M 1 $40M
TOTAL $1.3B
Largest Sprout Pharmaceuticals, Inc.
$1.0B (2015-08-20)

M&A Connections

Deals %
Exited to
Strategic(s)
100%
3 100%

 Subscribe to unlock this and 151,843
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.9K Private Equity Firms
  • 139K M&A Transactions
  • 148K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.1K M&A Advisors
    (Investment Banks and Law Firms)
  • 41K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.